Inactive Instrument

Actelion Ltd Stock Swiss Exchange

Stocks

End-of-day quote Swiss Exchange Other stock markets
- ^CHF	-

17-07-31	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
17-07-18	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE

17-07-31	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
17-07-18	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
17-07-18	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
17-06-09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
17-06-09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
17-06-09	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
17-05-22	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
17-05-18	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
17-04-20	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
17-04-18	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
17-04-05	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
17-03-31	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
17-02-22	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

20-04-06	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
17-10-31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
17-06-30	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
17-06-16	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
17-06-15	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

18-01-29	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
18-01-29	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
18-01-22	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
17-10-31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
17-10-30	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	+1.46%	+0.45%	+58.30%	+55.47%	53.79B
WUXI APPTEC CO., LTD.	+5.37%	+3.31%	+50.39%	+83.65%	54.69B
INSMED INCORPORATED	-0.02%	-2.52%	+4.44%	+409.20%	23.2B
BIONTECH SE	+1.51%	+2.27%	-15.11%	-14.86%	23.31B
WUXI BIOLOGICS (CAYMAN) INC.	+1.46%	+1.62%	+38.64%	-4.62%	20.03B
GENMAB A/S	+0.53%	-1.05%	+32.27%	-33.89%	17.31B
PHARMAESSENTIA CORPORATION	-1.67%	-6.00%	+163.95%	+284.69%	14.99B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.49%	+2.67%	+35.46%	+586.58%	15.36B
EXELIXIS, INC.	+0.32%	-1.11%	+24.60%	+180.09%	13.96B
Average	+1.15%	-0.71%	+43.66%	+171.81%	26.29B
Weighted average by Cap.	+1.88%	-0.93%	+43.62%	+134.47%

Employees

Sector